This Midcareer Investigator Award application seeks support to provide Dr. Freedland with protected time for patient-oriented research (POR) and to act as research mentor for junior faculty and 1 research fellow per year. Dr. Freedland's POR focuses on retrospective cohort studies with a transitioning emphasis on prospective clinical trials aimed at developing new and less toxic treatments to minimize prostate cancer treatment side effects and slow prostate cancer progression. Herein, he proposes a new trial comparing a carbohydrate-restricted diet vs. control for men with PSA recurrence after prostate cancer therapy aiming to slow the rate of PSA rise (lengthen the PSA doubling time), as an indirect measure of slowed prostate cancer growth. Secondary outcomes include weight loss and important prostate cancer biomarkers. Successful completion of this award will advance our understanding of lifestyle and other low toxicity interventions for prostate cancer as well as help educate the next generation of POR investigators.
Prostate Cancer is a major public health burden. Despite great efforts, and some progress, today, prostate cancer remains the number two cancer killer of men and a significant source of morbidity. New and less toxic treatments aimed at both minimizing treatment side-effects and slowing disease progression at sorely needed. Moreover, a new generation of investigators focused on patient-oriented research (POR) is also needed. To these ends, this Midcareer Investigator Award application seeks support to provide Dr. Freedland with protected time for POR and to act as research mentor for junior faculty and 1 research fellow per year. While Dr. Freedland's POR focus to date has been largely on retrospective cohort studies, this award coincides with a shift in his POR toward prospective clinical trials aimed at developing new and less toxic treatments to minimize prostate cancer treatment side effects and slow prostate cancer progression. Moreover, Dr. Freedland is a proven successful mentor to junior investigators in training and this award allows him to continue to spend the time necessary to mentor and help train the next generation of POR investigators.
|Vidal, Adriana C; Howard, Lauren E; De Hoedt, Amanda et al. (2018) Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy? Cancer :|
|Allott, Emma H; Masko, Elizabeth M; Freedland, Alexis R et al. (2018) Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer. Prostate Cancer Prostatic Dis 21:196-203|
|Fantony, Joseph J; Howard, Lauren E; Csizmadi, Ilona et al. (2018) Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study. Biomark Med 12:727-736|
|Allott, Emma H; Markt, Sarah C; Howard, Lauren E et al. (2018) Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. Cancer Epidemiol Biomarkers Prev 27:783-789|
|Everist, Mary M; Howard, Lauren E; Aronson, William J et al. (2018) Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. Urol Oncol :|
|Patel, Devin N; Jha, Shalini; Howard, Lauren E et al. (2018) Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol 25:998-1004|
|Jamnagerwalla, Juzar; Howard, Lauren E; Allott, Emma H et al. (2018) Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis 21:252-259|
|Freedland, Stephen J; Branche, Brandee L; Howard, Lauren E et al. (2018) Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. BJU Int :|
|Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203|
|Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588|
Showing the most recent 10 out of 75 publications